A Phase 2 interventional study of Atrasentan in Prostatic Neoplasms, sponsored by Abbott. Completed at 41 sites in 2 countries. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2006-08-15.
Sponsored by Abbott · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Prostatic Neoplasms by Abbott — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Abbott.
Among the 12 studies in Prostatic Neoplasms by Abbott, this one is one of 2 that started in 2002, is the only one in phase 2, and was the 3rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 12 studies in Prostatic Neoplasms by Abbott is open now. The open studies under Prostatic Neoplasms, anywhere →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 19 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5
First in 2001; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 255 across the 6 interventional studies, 729 across the 5 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Prostatic Neoplasms by Abbott, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evaluate the safety and efficacy of 10mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA.
This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atrasentan